High Neutrophil-to-Lymphocyte Ratio and Patients With Hemodialysis
ConditionHemodialysis Patient
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.
Eligibility criteria
Qualifiers
All cases with age ≥ 18 years from both sexes female and male, having end-stage renal disease (ESRD), who have been on hemodialysis for at least three months and divided to 4 groups according to the median of NLR and PLR
Disqualifiers
• Patients aged < 18 years old.
Patient with autoimmune disease.
Patient with liver cirrhosis.
Patients with immunodeficiency.
Trial design
Treatments tested in this trial
- neutrophil lymphocyte ratio and platelet lymphocyte ratio
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov